stockrow
Friday 6 November 2026
Export SNY’s income statement to Excel — free account
Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
46.90
0.01
−0.02%
Follow SNY
Alert me
Sanofi (SNY) Net income
Sanofi's net income for fiscal 2025 was $5.6B, down 6.04% from $5.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.5B. Over the past ten years it has ranged from $3.1B (fiscal 2019) to $14.1B (fiscal 2020); the current reading is higher than 45% of that period. Sanofi ranks 10th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $5.6B | (6.04%) |
| FY2024 | $5.9B | 1.76% |
| FY2023 | $5.8B | (33.73%) |
| FY2022 | $8.8B | 19.79% |
| FY2021 | $7.4B | (47.66%) |
| FY2020 | $14.1B | 347.58% |
| FY2019 | $3.1B | (38.20%) |
| FY2018 | $5.1B | (46.65%) |
| FY2017 | $9.5B | 82.94% |
| FY2016 | $5.2B | 9.47% |
Against its own ten years
Low $3.1B
High $14.1B
Ten-year median
$5.8B
Current reading's percentile
45
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| AZN AstraZeneca PLC compare | $13.3B |
| NVS Novartis AG compare | $10.0B |
| AMGN Amgen Inc. compare | $9.4B |
| BMY Bristol Myers Squibb Company compare | $9.2B |
| GSK GSK PLC Sponsored ADR compare | $6.3B |
| SNY Sanofi | $4.5B |
| PFE Pfizer Inc. compare | $4.1B |
| GILD Gilead Sciences, Inc. compare | −$3.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on SNY
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement